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Commentary:
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Abstract
Human intestinal spirochetosis (HIS) has been thought to be  largely 
asymptomatic. The fuzzy brush border seen in HIS is due to an anaerobic 
spirochaete of the Brachyspira genus aligned perpendicular to the colonic 
mucosa. Inflammatory submucosal reaction is rare. However several species of 
Brachyspira found in domestic animals cause diarrhoeal disease and one B. 
pilosicoli has been documented to transfer freely between dogs, chickens, pigs 
and humans. This commentary reviews an article which finds evidence of  
Brachyspira spp. infection in up to 1/3rd  of patients with irritable bowel 
syndrome with diarrhoea. It is unclear whether current treatments are truly 
effective in the long term. Further work is needed since it remains unclear 
whether the association is cause or effect.
Human intestinal spirochetosis (HIS) has been recognised since the early days of 
histopathology but similar to Helicobacter pylori, its presence is inconsistently 
linked to disease so it is usually dismissed as a harmless commensal(1). The 
condition is caused by Brachyspira, a genus of anaerobic bacteria whose spiral 
form and periplasmic flagellae allows them to easily glide through colonic mucus 
which is their normally habitat. They were first reported in 1719 when Van 
Leeuwenhoek, reported moving spiral “animalcules” in his own stools. HIS can 
be identified from a blurry red fringe on the intercryptal epithelial surface, seen 
throughout the colon in sections stained with haematoxylin and eosin. Electron 
microscopy shows myriads of organisms lined up, perpendicular to the mucosa, 
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the proximal tip embedded in but not penetrating an invagination of the host cell 
membrane (Figure). Conventional histology finds HIS in 0.4% in a hospital series 
in Japan and 2.3% in a population survey in Sweden(2) but 39% in male 
homosexuals in the UK with a link to ora-anal contact but not HIV status(3). 
Many cases of HIS appear to be asymptomatic, one large Australian survey of 
113 cases of HIS found only 10 cases with obvious inflammation, 6 of whom had 
other explanations for the inflammatory response(4). Detailed morphological 
examination in isolated case reports suggests that gastrointestinal symptoms 
only occur when spirochetes invade beyond the surface epithelium, which 
appears to be rare and may require additional factors(2).
Veterinary scientists have a rather different perspective since B. pilosicoli, B. 
intermedia, B. alvinipulli and particularly B. hyodysenteriae, can all cause 
diarrhoea and weight loss in domestic animals including dogs, chickens and pigs 
(5), an problem linked to overcrowding and poor hygiene due to intensive 
farming practices. B. pilosicoli can survive in soil and infect humans particularly 
in rural communities where the organism appears to move freely between 
humans and pigs, dogs and chickens(6). Although in this population most 
infections appear asymptomatic those with watery stools were more likely to 
harbour B. pilosicoli. The two other Brachyspira species, B. aalborgi and B. 
hominis appear to be primate adapted, being found in humans and subhuman 
primates(5) where they mostly cause no inflammatory response. An Australian 
survey found that B. pilosicoli infection is largely confined to rural aboriginals 
(15%), with B. aalborgi being less prevalent (5%) but found in both rural and 
urban living individuals. Interestingly, having B. aalborgi increased the risk of 
having B. pilosicoli to 12-fold as did a co-infection with Blastocystis(7). 
Comparative genome sequencing of the various Brachyspira species suggests B. 
aalborgi to be evolutionarily the most divergent species of the genus(8). 
Significantly the primers most commonly used in human microbiome studies fail 
to detect Brachyspira 16S rRNA, which may explain why it has been “hidden in 
plain sight”(9). The B. aalborgi genome is highly heterogeneous with very low 
GC% and lacks the potentially pathogenic genomic region harboured by the 
other Brachyspira spp. (10).
The current paper (Jabber, 2020) goes further than previous studies in 
attempting to separate the effect of different species (B. aalborgi /hominis 
/pilosicoli) and their distribution within the colonic mucus layers 
(deep/superficial). Mass spectrometry provided proteomic evidence of 
Brachyspira within the deep adherent mucus layer of 3/22 IBS patients but 0/14 
healthy controls. Analysis of a further 40 IBS patients and 17 controls showed 
that overall, 14/50 patients had detectable Brachyspira spp. shown by ≥2 
methods (PCR or immunofluorescence). Membrane associated spirochaetosis 
was not found in controls but was found in 9/43 patients with conclusive results 
from immunofluorescence, seven of whom had IBS-D. When just membrane 
associated cases were considered, most of whom had B. aalborgi, stool 
frequency was greater, stools looser and transit faster but extracolonic 
symptoms were less supporting idea that the origin of symptoms was more gut 
than brain. However, the increase in eosinophils, mast cells and plasma cells in 
those with Brachyspira spp. was seen in both mucus and membrane associated 
taxa, reducing one’s confidence that these are directly linked. There was an 
increase in many mucosal proteins in those with Brachyspira spp., the most 
notable being guanylin, a secretagogue which might well explain loose stools. 
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Only four patients were treated with  open label metronidazole. Three of these 
showed a fall in IBS-SSS of >50 at 1 year but two would still be described as 
moderate/severely symptomatic. With such a small cohort no comment is really 
appropriate apart from the fact that a proper randomised placebo-controlled trial 
is warranted. 
Part of the confusion about whether Brachyspira causes symptoms could be that 
studies to date have not distinguished between the significantly different 
Brachyspira spp. and strains, of which only a minority cause disease.  It remains 
also possible that rather than causing IBS, having IBS-D creates an environment 
where Brachyspira spp. can flourish. Given Brachyspira species are ubiquitous, 
factors which facilitate colonisation like diet (11) and antibiotic treatment (12), 
may explain differences in colonisation rates. It is possible that the increased 
risk of being prescribed antibiotics associated with having  IBS (13) may 
contribute to the increased prevalence of Brachyspira spp.
Another possible factor allowing Brachyspira spp. to cause inflammation might 
be impaired mucus barrier. IBS patients often report stress which can lead to 
impaired mucus barrier at least in animals(14). Co-infection with other enteric 
pathogens exacerbates the inflammatory response in B. pilosicoli infection(15) 
so it is possible that some of the post-infectious IBS cases have Brachyspira spp. 
which causing ongoing symptoms after the original infection has subsided.
Many clinicians reading this will be wondering whether they should be 
reassessing their IBS-D patients, since if the current cohort is representative, 
around 1/3 may harbour Brachyspira spp.. The current data suggest caution, 
particularly given that in this study metronidazole may have driven Brachyspira 
to relocate intracellularly with unknown consequences. Plainly we have a lot to 
learn. More work on the basic biology in animal models would seem necessary to 
choose the correct antibiotic for a randomised placebo-controlled trial in 
humans, which would be an important step forward in this fascinating area. 
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Legend to figure
EM from (1) showing surface of colonic epithelial cells with numerous 
spirochaetes (S) orientated in the long axis of the cells. Arrows indicate 
microvilli. Reproduced by permission of the publisher
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